Fusion Pharmaceuticals’ (FUSN) “Hold” Rating Reaffirmed at TD Cowen

TD Cowen reissued their hold rating on shares of Fusion Pharmaceuticals (NASDAQ:FUSN) in a research note issued to investors on Tuesday morning, Benzinga reports.

FUSN has been the topic of a number of other research reports. Jefferies Financial Group reiterated a hold rating and set a $21.00 price objective (up previously from $10.00) on shares of Fusion Pharmaceuticals in a research report on Tuesday, March 19th. Raymond James reiterated a market perform rating on shares of Fusion Pharmaceuticals in a research report on Tuesday, March 19th. Truist Financial reiterated a hold rating and set a $21.00 price objective (up previously from $11.00) on shares of Fusion Pharmaceuticals in a research report on Tuesday, March 19th. Jonestrading reiterated a hold rating on shares of Fusion Pharmaceuticals in a research report on Wednesday, March 20th. Finally, Wedbush downgraded Fusion Pharmaceuticals from an outperform rating to a neutral rating and set a $24.00 price objective on the stock. in a research report on Tuesday, March 19th. Thirteen investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of Hold and an average price target of $20.25.

Fusion Pharmaceuticals Stock Performance

NASDAQ FUSN opened at $21.26 on Tuesday. The company has a market cap of $1.80 billion, a PE ratio of -14.46 and a beta of -0.73. The stock’s 50 day simple moving average is $15.48 and its 200-day simple moving average is $9.54. Fusion Pharmaceuticals has a 1-year low of $2.31 and a 1-year high of $21.55. The company has a debt-to-equity ratio of 0.16, a current ratio of 15.01 and a quick ratio of 15.01.

Fusion Pharmaceuticals (NASDAQ:FUSN) last released its earnings results on Wednesday, March 20th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.05). Fusion Pharmaceuticals had a negative net margin of 4,136.55% and a negative return on equity of 46.59%. As a group, equities research analysts anticipate that Fusion Pharmaceuticals will post -1.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Fusion Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in FUSN. Signaturefd LLC increased its stake in Fusion Pharmaceuticals by 883.0% during the fourth quarter. Signaturefd LLC now owns 2,949 shares of the company’s stock worth $28,000 after acquiring an additional 2,649 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Fusion Pharmaceuticals by 2,064.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,008 shares of the company’s stock valued at $29,000 after buying an additional 2,869 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of Fusion Pharmaceuticals in the second quarter valued at $29,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Fusion Pharmaceuticals in the first quarter valued at $49,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Fusion Pharmaceuticals in the third quarter valued at $51,000. Institutional investors and hedge funds own 72.85% of the company’s stock.

Fusion Pharmaceuticals Company Profile

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.